Kala Bio (KALA) Q2 Loss Widens 15%
Kala Bio (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss per share of $1.71 (GAAP). Marginally wider than the analyst estimate of $1.70 (GAAP). The company remains pre-commercial, so there was no revenue to report or compare to expectations. Overall, the quarter was defined by continued progress in its key clinical trial for KPI-012 for persistent corneal epithelial defects (PCED), but also higher operating losses and a shrinking cash position.
Source: Analyst estimates for the quarter provided by FactSet.
Kala Bio is developing new treatments for serious eye diseases using its proprietary mesenchymal stem cell secretome (MSC-S) platform. As a clinical-stage biotech, it currently has no approved or marketed products and generates no revenue. Its lead candidate, KPI-012, is being evaluated for treating persistent corneal epithelial defects (PCED), a rare eye disorder affecting an estimated 100,000 people in the United States.
Source Fool.com
